ニュース
58 分
Asianet Newsable on MSNEli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s SoldBimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...
Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...
Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, ...
The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...
Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...
4 日on MSN
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する